ABSTRACT: cTnI P82S (cTnI P83S in rodents) resides at the I-T arm of cardiac troponin I (cTnI) and was initially identified as a disease-causing mutation of hypertrophic cardiomyopathy (HCM). However, later studies suggested this may not be true. We recently reported that introduction of an HCM-associated mutation in either inhibitory-peptide (cTnI R146G ) or cardiacspecific N-terminus (cTnI R21C ) of cTnI blunts the PKAmediated modulation on myofibril activation/relaxation kinetics by prohibiting formation of intrasubunit contacts between these regions. Here, we tested whether this also occurs for cTnI P83S . cTnI P83S increased both Ca 2+ binding affinity to cTn (K Ca ) and affinity of cTnC for cTnI (K C−I ), and eliminated the reduction of K Ca and K C−I observed for phosphorylated-cTnI WT . In isolated myofibrils, cTnI P83S maintained maximal tension (T MAX ) and Ca 2+ sensitivity of tension (pCa 50 ). For cTnI WT myofibrils, PKA-mediated phosphorylation decreased pCa 50 and sped up the slow-phase relaxation (especially for those Ca 2+ conditions that heart performs in vivo). Those effects were blunted for cTnI P83S myofibrils. Molecular-dynamics simulations suggested cTnI P83S moderately inhibited an intrasubunit interaction formation between inhibitory-peptide and N-terminus, but this "blunting" effect was weaker than that with cTnI R146G or cTnI R21C . In summary, cTnI P83S has similar effects as other HCM-associated cTnI mutations on troponin and myofibril function even though it is in the I-T arm of cTnI.
■ INTRODUCTION
Hypertrophic cardiomyopathy (HCM), a familial myocardial condition often correlated with myofilament contractile protein mutations, has been identified as a major autosomal dominant disease accompanied by a morbidity of 1 per 500 individuals. 1, 2 To date, over 900 HCM-associated mutations have been identified in 24 genes, 3, 4 and a majority of these mutations reside in the thick filament proteins, such as cardiac myosin binding protein C (cMyBP-C), myosin, and titin. 4, 5 Despite this, several mutations have also been reported in one of the thin filament regulatory proteins, cardiac troponin I (cTnI), which is the actomyosin ATPase inhibitory subunit of the cardiac troponin (cTn) complex. 5 cTn is the key regulator for muscle contraction, and it regulates the thin and thick filaments interaction in a Ca 2+ -dependent manner. 6 In diastole, cardiac troponin C (cTnC) presents in its "closed" conformation, and cTnI strongly binds with actin (weak interaction with cTnC), thus inhibiting actin−myosin interaction. 6, 7 In systole, with the rise of intracellular Ca 2+ in cardiomyocytes, Ca 2+ binding to the cTnC site II induces an "open" confirmation of the regulatory N-domain and increases its interaction with cTnI switchpeptide. 6, 8 Consequently, this results in a decreased binding of cTnI inhibitory-peptide with actin and increased tropomyosin mobility that the myosin binding sites were exposed on actin, thus allowing myosin interaction with actin and the formation of "cross-bridges". 6 During β-adrenergic stimulation, cTnI is phosphorylated by protein kinase A (PKA) at sites Ser-23/Ser-24 (S23/S24), which reside at the cardiac-specific N-terminus of cTnI. 9 We 10 and others 9,11−13 have demonstrated that this PKA-mediated phosphorylation weakens cTnC−cTnI (C−I) interaction, decreases the Ca 2+ sensitivity (pCa 50 ) of cardiac muscle tension production, increases Ca 2+ dissociation rate (k off ) from cTnC, elevates cross-bridge cycling kinetics, and accelerates cardiac muscle relaxation. Additionally, we demonstrated that PKA phosphorylation of isolated rat cardiac myofibrils with WT-cTn accelerates and shortens the initial, slow-phase of relaxation (especially during submaximal activation that the heart operates in vivo) that is considered to reflect cross-bridge detachment rate and, perhaps, deactivation of thin filament. 10 Since the first HCM-associated cTnI mutations were reported by Kimura et al. in 1997, 14 there have been at least 29 mutations in cTnI putatively suggested to be contributory to HCM. 5, 15 Initial studies by Niimura et al. identified cTnI
P82S
(cTnI P83S in rodents) as a disease-causing mutation of the lateonset hypertrophy, and its pathogenicity is not clear. 16 Later on, Frazier et al. reported an African American individual (32-year-old, women) with severe HCM (a family history of HCM and sudden cardiac death), and identified that she has both the P82S mutation in cTnI and the R453S mutation in cardiac β-myosin heavy chain (MYH7). 17 By analyzing DNA from a panel of 100 individuals, Frazier et al. also determined that cTnI P82S presents in ∼3% of healthy African Americans. Thus, they concluded that cTnI P82S is likely a non-disease-causing amino acid variant. 17 Using transgenic mice, Ramirez-Correa et al. reported that cTnI P83S showed normal cardiac contractility when young, but displayed diastolic dysfunction (for instance, impaired ejection and relaxation time, and prolonged isovolumetric relaxation time) with aging. 18 Additionally, they found that cTnI P83S mice blunted the β-adrenergic response and impaired myofilament cooperativity. 18 Considering this, it is of importance to further investigate whether cTnI P82S alters myofibril contraction/relaxation kinetics, and whether structural−function changes are similar to those of other HCMassociated cTnI mutations.
Among all HCM cTnI mutations, cTnI R146G (located in the inhibitory-peptide) and cTnI R21C (resided at the cardiac-specific N-terminus) have been extensively studied by several groups. 19−33 Recently, we also reported the blunted β-adrenergic response for both cTnI HCM-associated mutations. 34, 35 Both mutations significantly left-shifted (increased) Ca 2+ binding affinity to cTn (K Ca ) and the affinity of cTnC for cTnI (K C−I ). PKA-mediated phosphorylation of cTnI induced a similar reduction of K Ca for all complexes, but the reduction in K C−I normally seen with cTnI WT did not occur for either mutation in cTnI. Both mutations increased Ca 2+ sensitivity of tension (pCa 50 ) while maximal tension (T MAX ) was maintained. PKA-mediated phosphorylation of cTnI right-shifted pCa 50 for cTnI WT myofibrils, however not for either mutation. 34 PKAmediated phosphorylation also sped up the initial, slow-phase relaxation for cTnI WT myofibrils, especially at those submaximal Ca 2+ conditions that the heart performs in vivo. Importantly, this effect on relaxation was eliminated for both cTnI R146G and cTnI R21C myofibrils, as was PKA-mediated reduction in K C−I . 34 Our results also suggested that the structural basis of how these two mutations blunted the ability of PKA-mediated phosphorylation on cTnC−cTnI interaction, myofibril contraction, and relaxation is prohibiting the formation of an intrasubunit contact between the cTnI N-terminus (NcTnI) and the inhibitory-peptide of cTnI, which further precipitates reduction of interaction between the cTnI switch-peptide and cTnC hydrophobic-patch. 34, 35 To understand whether the above effects occur in all HCMassociated cTnI mutations or they are restricted to the mutations in specific regions (such as N-terminus, inhibitorypeptide region), in the present work, we studied the HCMassociated mutation cTnI P83S that is located in the I-T arm region (see Figure 1 for the location). Compared to cTnI WT , cTnI P83S also increased K Ca and K C−I , similar to what we previously reported on cTnI R146G and cTnI R21C , but with less degree (extent) of increment. Introduction of the bisphosphomimic substitutions on cTnI P83S eliminated the reduction of K C−I normally seen in cTnI WT ; however, it also blunted the reduction of K Ca that is detected in both cTnI WT , cTnI R146G and cTnI R21C . In isolated myofibrils, both pCa 50 and T MAX were maintained for cTnI P83S exchanged myofibril, but with PKA-mediated phosphorylation, cTnI P83S also eliminated the right-shift of pCa 50 normally seen with cTnI WT exchanged myofibrils. Our computational modeling results suggested that cTnI P83S moderately inhibited the formation of the intrasubunit interaction between cTnI inhibitory-peptide and NcTnI that is normally observed for WT-cTn with phosphorylation of cTnI S23/S24; however, this "blunting" effect was much weaker than cTnI R146G and cTnI R21C . Thus, cTnI P83S appears to have effects on cTn and myofibril function similar to HCM-associated mutations in the N-terminus and inhibitory-peptide regions of cTnI, but the effect on Ca 2+ sensitivity of myofibril tension and PKA modulation of relaxation may be more moderate, and this may at least partially explain conflicting reports and conclusions in the literature.
■ EXPERIMENTAL AND THEORETICAL METHODS
Proteins, cTnC Labeling, cTnI Phosphorylation, and cTn Complex Reconstitution. WT rat cTnC, cTnI, and cTnT were constructed and expressed as described previously. 3 6 cTnC C 3 5 S , cTnI S 2 3 D / S 2 4 D , cTnI P 8 3 S , and cTnI P83S/S23D/S24D were constructed from WT cTnC and cTnI plasmids, respectively, using a site-directed mutagenesis kit (Stratagene, La Jolla, CA). All WT and mutant proteins were expressed with a pET-24 vector (Novagen, Madison, WI) which contains a T7 promoter, a lac operator, and a kanamycin resistant gene. Finally, the expressed constructs were confirmed by DNA sequence analysis.
The cTnC C35S substitution was labeled with a fluorescent probe {N-[2-(iodoacetoxy)ethyl]-N-methylamino-7-nitrobenz-2-oxa-1,3-diazole (IANBD, M w = 406.14, Life technologies, Cat No: I-9) at position C84 (cTnC IANBD C35S ) in the dark overnight at 4°C to monitor the Ca 2+ −cTn (K Ca ) and cTnC−cTnI (K C−I ) binding affinities, as described previously. 10,34,37−40 The labeling efficiency (also known as percentage of labeling) was obtained by comparing the IANBD fluorophore versus protein concentration ratio. 10, 39 The protein's concentration was determined using the Bio-Rad protein assay (based on the Bradford method), and the IANBD fluorophore concentration was computed using the maximal absorbance of labeled protein at a wavelength ∼481 nm dividing by IANBD's extinction coefficient (21 000 M −1 cm −1 ). 10, 39 The labeling efficiency of cTnC C35S substitution was ∼90%. Whole cTn complexes were formed using rat cTnC (WT or cTnC IANBD C35S ), rat cTnI (WT, S23D/S24D, P83S, or P83S/S23D/S24D), and rat cTnT (WT) at a 1:1:1 molar ratio and then dialyzed through a series of buffers with gradually decreased KCl concentration at 4°C (without stirring) as described previously. 41, 42 Here, cTn c o m p l e x e s w i t h c T n C I A N B D C 3 5 S , cTnI S 2 3 D / S 2 4 D ( o r cTnI P83S/S23D/S24D ) were only used for Ca 2+ −cTn (K Ca ) binding measurement.
Steady-State Fluorescence Measurements. Steady-state fluorescence measurements were performed by a luminescence spectrometer (PerkinElmer LS50B) at 15°C as described previously. 10, 34, 39, 40 Solution applied for this measurement contains (in mM) the following: 150 KCl, 20 MOPS, 3 MgCl 2 , 2 EGTA, and 1 DTT (pH 7.0). Fluorescence signal was recorded at ∼530 nm during the titration of (1) Ca 2+ into 2 mL of cTn IANBD C35S (0.6 μM), or (2) cTnI variants (WT, S23D/S24D, P83S or P83S/S23D/S24D) into 2 mL of cTnC IANBD C35S (0.6 μM) in the presence of Ca 2+ (100 μM). The concentration of free Ca 2+ was computed using Maxchelator. 43 The Ca 2+ sensitivity (measured as pCa 50 , the pCa (pCa = −log [Ca 2+ ]) value at halfmaximal fluorescence signal change) was collected by fitting the titration curve with the S-shaped Hill equation as described previously. 44 Here, the reported data are the means ± SE of 4− 6 successive titrations.
Ethical Approval and Tissue Preparation. All animal procedures were carried out according to the U.S National Institutes of Health Policy on Humane Care and Use of Laboratory Animals and were approved by the University of Washington (UW) Institutional Animal Care and Use Committee (IACUC). Animals were housed in the Department of Comparative Medicine at UW and cared for in accordance with UW IACUC procedures. After initial exposure to isoflurane (3−5% in oxygen), pentobarbital (50 mg/kg) was intraperitoneal injected to male, Sprague−Dawley rats (3 months old, 150−250 g) for anesthesia. When the rat had no reflexive response, its heart was quickly excised and dissected in oxygenated physiological saline solution, which contains (in mM) the following: 100 NaCl, 2.5 KCl, 24 NaHCO 3 , 1 Na 2 HPO 4 , 1 MgSO 4 ·7H 2 O, and 1 CaCl 2 . 45 After this, both ventricles were cut open, and the whole heart was demembranated in skinning solution containing (in mM) the following: 100 KCl, 9 MgCl 2 , 4 Na 2 ATP, 5 K 2 EGTA, 10 MOPS, 1% Triton X-100, pH 7.0, 50% v/v glycerol, and 1:100 dilution Protease-Inhibitor-Cocktail (PI) (Sigma-Aldrich, Cat. No.: P8340) overnight at 4°C. 46, 47 The heart was then washed three times in the same buffer without Triton X-100 and kept at −20°C for use for up to 1 week. Myofibrils from the left ventricles (LV) were used for the mechanical measurements described below.
Solutions. Solution composition (for mechanical measurements) was determined using an iterative algorithm, which calculates the equilibrium concentration of ligands and ions according to published affinity constants. 48 The relaxing solution has the composition as follows (in mM): 80 49 All mechanical measurements were carried out at 15°C. The Ca 2+ levels (measured as pCa) of activating solutions were adjusted by adding CaCl 2 .
Exchange of Recombinant cTn Complexes into Myofibrils. Muscle bundles obtained from the rat LV were rinsed twice in Rigor solution, with a composition of (in mM) the following: 100 KCl, 50 Tris, 1 EGTA, 2 MgCl 2 , 1 DTT, and 1:100 dilution of PI. Then, the muscle bundles were homogenized for two 30 s pulses at a high speed on ice. cTn complexes containing cTnI WT or cTnI P83S (∼1 mg/mL) were passively exchanged into isolated rat myofibrils in a buffer containing (in mM) the following: 150 KCl, 5 MgCl 2 , 20 MOPS, 4 ATP, 2 EGTA, 1 DTT, and 1:100 dilution of PI (pH 7.0) on a slow rocker overnight at 4°C. 10, 34 Following overnight exchange, myofibrils were washed with relaxing buffer containing ∼1 mg/mL bovine serum albumin (BSA) twice for 30 min to remove any nonspecifically bound exogenous cTn. Myofibrils were then equally split: one-half was used to collect the kinetic/mechanism results prior to PKA treatment, and the other half was incubated with 200 μL relaxing solution containing 100 units of PKA and 6 mM DTT for 45 min at 20°C for studying the effects of PKA-mediated phosphorylation.
Myofibril Mechanical and Kinetics Measurements. Myofibril mechanical/kinetics studies were carried out on a home-built setup as described previously. 10, 50, 51 In brief, single or small bundles of ∼2−4 cardiac myofibrils were attached between two glass microneedles (one is straight and another is bent) forged from borosilicate glass capillary tubes (OD 1.0 mm, ID 0.5 mm, Sutter Instruments, Novato, CA), and perfused with activating and relaxing buffers that can be rapidly switched. The initial sarcomere length (SL) of myofibril was set as ∼2.3 μm. Here, the straight microneedle is mounted to one end of the myofibril and was applied to rapidly shorten and restretch the myofibril through a computer interface and a piezocontroller motor (PZT Servo controller, LVPZT amplifier, Physik Instrumente, Irvine CA). The bent microneedle acts as a force transducer (FT) to hold the other end of the myofibril, and it deflected with application of force in a predictable mode. 50 The stiffness of FT applied for this study ranged from 5 to 9 nN μm −1 , and the value was measured under a 40× lens by bending the microneedle with a set of force using a galvanometer. The displacement of FT was recorded by a dual-diode system, and correlated to tension development. At the end of each experiment, a calibration curve was performed in which the FT needle was moved in 1 μm steps using micromanipulators (MP-285, Sutter Instruments, Novato, CA) over the range of the diodes. The relaxing (10 Step, Warner Instruments Corporation, Hamden, CT). 50−52 Activation−relaxation results were measured at 15°C and then fit as described previously. 50,52−54 The kinetics of myofibril activation (k ACT ) with a rapid increase in Ca 2+ level was collected from a single exponential rise to a maximum. Once the myofibril was activated, a rapid release−restretch protocol (the myofibril was 20% shorting in optimal length suddenly, and after 25 ms of unloaded shortening period, the myofibril was rapidly stretching back to the original length) was applied to get the rate of tension redevelopment (k TR ). 54 The rate of slow-phase relaxation (k REL,slow ) was computed from the slope of a regression line fit to the force trace and then normalized to the entire tension amplitude. The duration of slow-phase relaxation (t REL,slow ) was collected from the onset of buffer switching to the shoulder marking the starting of fastphase relaxation. An apparent change in slope or in "signal-tonoise" ratio was applied to determine at the transition from slow-to fast-phase. The rate for fast-phase relaxation (k REL,fast ) was fitted by a single exponential decay. In some cases (decay cannot be well-described by a single exponential), a t 1/2 estimation was made and then converted to a rate τ = ln(2)/ t 1/2 . In this study, myofibrils that contracted over 10% of their optimal length were considered as nonisometric and excluded from the analysis.
cTnI Phosphorylation Profile. The cTnI phosphorylation profile was quantified using Western blot by calculating the amount of phosphorylated cTnI relative to the total amount of cTnI. 10, 34 The phosphorylated cTnI was detected using a rabbit polyclonal to cTnI (phospho S22 + S23, from abcam, cat. no.: ab58545) as primary antibody (1:1000) and goat antirabbit IgG-HRP (Santa Cruz Biotechnology, sc-2004) as secondary antibody (1:5000). The total cTnI was quantified using antibodies rabbit polyclonal lgG to troponin I (H170, from Santa Cruz Biotechnology, sc-15368) (1:1000) and goat antirabbit IgG-HRP (1:5000).
Computational Modeling. The initial structure of the cTn complex was built up on the basis of the crystal structure of Takeda et al. 55 with the addition of the N-terminus of cTnI from the NMR structure provided by Howarth et al. 56 To mimic phosphorylation, a bis-phosphomimics model (cTnI S23D/S24D ) was constructed by mutating S23/S24 of cTnI to aspartic acid (D). 57 The models were immersed in a truncated rectangular box with TIP3P water molecules, which extended minimally 14 Å away from any solute atoms. 58 Then, K + and Cl − ions were added to neutralize the systems, and brought to 150 mM ionic strength. The fully solvated systems contained 112 739 (cTnI P83S cTn model) and 112 740 (cTnI P83S/S23D/S24D cTn model) atoms, respectively. Prior to the MD simulations, we performed three steps of minimizations. Next, for each of the two simulation systems, three independent sets of 150 ns MD simulations were carried out under 300 K and the NPT ensemble using NAMD 2.9 59 and the CHARMM27 force field. 60 The SHAKE procedure was applied, and the time step was set as 2.0 fs. 61 During the sampling process, the coordinates were saved every 10 ps (cTnI P83S cTn model) and 2 ps (cTnI P83S/S23D/S24D cTn model), respectively. The stability between site II Ca 2+ and its coordinating residues (Asp-65, Asp-67, Ser-69, Thr-71, Asp-73, and Glu-76) of cTnC was monitored by calculating the corresponding distances for each 150 ns simulation as described previously. 34, 35, 39, 62 The residue−residue contacts between cTnC and key regions of cTnI (N-terminus, inhibitory-peptide, and switchpeptide regions) were monitored over the course of the entire 450 ns simulations. Contacts between two residues were defined as described previously, with a carbon−carbon distance of ≤5.4 Å and a distance between any other noncarbon atoms of ≤4.6 Å being a contact. 39, 62 Contacts between the NcTnCswitch-peptide of cTnI and cTnC-inhibitory-peptide of cTnI were monitored. The intrasubunit contact between N-terminus and inhibitory-peptide of cTnI were also recorded. For each contact pair, the portion of the simulation time that these residues contacted with each other was calculated for both simulation systems. Lastly, an I−T arm interhelical angle analysis was performed. The interhelical angles were computed using interhlx (K. Yap, University of Toronto). We calculated the angle between the two structural helices in cTnI as defined by cTnI residues 45−82 and 91−137.
Statistics. Comparison between groups of data was carried out using the one-way analysis of variant (ANOVA) test as appropriate. All experimental data are expressed as mean ± SE, and n represents the number of experimental samples in each group; the reported computational (MD simulations) results are expressed as mean ± SD, and n equals 3. Results with p < 0.05 were considered statistically significant.
■ RESULTS
Steady-State Fluorescence Measurements of K Ca and K C−I . The effects of cTnI P83S mutation ± bis-phosphomimic substitutions on cTn-K Ca and K C−I were determined by steadystate fluorescence measurements using a fluoroprobe IANBD, as previously described. 10, 34, 39 IANBD, a sulfhydryl-reactive and environment-sensitive extrinsic fluorophore, has been widely applied for monitoring the intramolecular interactions of proteins. The labeling of IANBD at C84 of cTnC C35S reflects conformational and environmental changes of NcTnC that arise from Ca 2+ binding and/or interaction with cTnI. 10, 34, 38, 39 We first measured the conformational changes with Ca 2+ binding to cTn containing either cTnI P83S or cTnI P83S/S23D/S24D compared with the cTnI WT set. As shown in the Ca 2+ titration curves (Figure 2A ), the Ca 2+ sensitivity of the fluorescence intensity (reported as pCa 50 ) was left-shifted 0.09 pCa units, from 7.18 ± 0.02 (cTn with cTnI WT ) to 7.27 ± 0.02 (cTn with cTnI P83S ). Consistent with our previous finding, 10, 34 introduction of bis-phosphomimic substitutions on cTnI WT (cTnI S23D/S24D ) also reduced K Ca , resulting in a 0.27 pCa unit decrease (right-shifted to 6.91 ± 0.03). Interestingly, with introduction of bis-phosphomimic substitutions on cTnI P83S , this effect was completely eliminated (pCa 50 = 7.24 ± 0.03 for cTn with cTnI P83S/S23D/D24D ). cTnC-cTnI (C−I) interaction acts as a "gatekeeper" in transferring Ca 2+ signal to other myofilament proteins to initiate cardiac muscle contraction. Therefore, we next measured how introduction of cTnI P83S mutation ± bisphosphomimic substitutions affects the affinity of cTnC for cTnI (K C−I ). As shown in Figure 2B , the IANBD fluorescence signal increased with the titration of cTnI in solution containing 0.6 μM cTnC IANBD C35S , and there was no further increase beyond 0.6 μM cTnI, suggesting strong binding of cTnI to cTnC such that 1:1 binding was achieved. Similar to K Ca , cTnI P83S also left- P83S . The extent of exchange (exchange efficiency) for this procedure was periodically determined by exchanging cTn containing a cTnT labeled at the N-terminus with a c-myc tag, to compare the c-myc tag band versus the native cTnT band in gels and with Western blot analysis. 10 We consistently saw >80% endogenous cTn replacement by cTn containing the cmyc tagged cTnT in myofibrils using this approach, 10 suggesting our exchange protocol is very efficient and changes in contractile parameters should be attributed to the exchanged cTn containing cTnI P83S . In this study, we did five batches of passive exchange for both cTn species containing either cTnI WT or cTnI P83S at the same time. Following exchange and washing, myofibrils were equally split into two parts, with one-half used to collect the kinetics/ mechanics results before PKA phosphorylation, and the other half to study the effects of PKA-mediated phosphorylation (see Methods section). The phosphorylation profile for cMyBP-C and titin (which can also be phosphorylated by PKA incubation) was not measured; however, this should be quite similar for each group as paired comparisons of myofibrils containing cTnI P83S versus cTnI WT were made from each heart. Rats generally have high β-adrenergic stimulation; thus, the native myofibrils (directly from the rats) displayed higher PKA phosphorylation levels of cTnI. Since the recombinant cTn containing either cTnI WT or cTnI P83S was not phosphorylated, the cTnI phosphorylation extent in exchanged myofibrils (prior to PKA treatment) was inversely correlated with the exchange efficiency. As shown in Figure 3A , a fairly small amount of residual phosphorylated cTnI was present in every exchange preparation since the exchange efficiency was not 100%. In a comparison of the cTnI phosphorylation extent for native versus exchanged myofibrils (prior to PKA treatment), the exchange efficiencies for cTn containing cTnI WT and cTnI
P83S
were 89% and 91%, respectively, further confirming high exchange efficiency. After PKA treatment, the cTnI phosphorylation level was significantly increased, resulting in a high level of cTnI phosphorylated, which is consistent with our previous observation. 10, 34 cTnI-P83S Mutation Has No Effects on Myofibril Contraction and Relaxation. The effect of cTnI P83S mutation on tension development and relaxation kinetics (at 15°C) was determined from isolated rat LV cardiac myofibrils exchanged with cTn containing cTnI
, and then compared with the WT cTn complex. Myofibrils mounted by two glass microtools were exposed to continually flowing pCa buffer that was rapidly switched, from relaxing buffer (pCa 9.0) to either maximal (pCa 4.0) or submaximal (pCa 5.4, pCa 5.6 and pCa 5.8) [Ca 2+ ] buffer, and finally back to 9.0. Representative example tension traces for cTnI WT and cTnI P83S exchanged myofibrils during the submaximal [Ca 2+ ] activation−relaxation protocol (at pCa 5.4) are presented in Figure 4 . The magnitude of tension and kinetic for rat LV myofibrils exchanged with cTn containing cTnI WT or cTnI P83S is summarized in Table 1 Figure 5A ). Tension was also measured at multiple submaximal Ca 2+ levels, and the pCa 50 was just slightly left-shifted (p > 0.05, not statistic significantly, Figure 5B a Values given are mean ± SE. Number in parentheses is number of myofibrils. *p < 0.05 vs WT, and * ,$ p < 0.05 vs WT+PKA. ), k ACT did not differ for the cTnI P83S (3.7 ± 0.2 s −1 ) exchanged myofibrils either pCa 4.0, or pCa 5.4 ( Figure  5C ). As previously reported for rodent (or canine) cardiac myofibrils, 10, 34, 49, 54 k ACT was significantly slower at submaximal Ca 2+ activation than during maximal Ca 2+ levels for both cTnI WT and cTnI P83S exchanged myofibrils, suggesting the Ca 2+ sensitivity of cardiac contraction kinetics is also maintained upon introduction of the cTnI P83S mutations. Once the activation was in or near steady-state, we applied a rapid release−restretch protocol on myofibrils to collect the rate of tension redevelopment (k TR ). This k TR protocol is designed to measure the myosin cross-bridge attachment rate and the subsequent tension generation when Ca 2+ −Tn binding is near steady-state (for example: thin filament is activated), 47 and thus can help to differentiate the contribution of Ca 2+ -dependent thin filament activation vs cross-bridge cycling to k ACT . For all measured conditions, k TR was faster than k ACT , as we previously reported, 10, 34 again suggesting thin filament activation (for rat cardiac myofibrils) is rate-limiting at 15°C. Additionally, comparison of the k ACT /k TR ratio serves as a good indicator to show whether thin filament activation is more rate-limiting in the cTnI P83S exchanged myofibrils with respect to the cTnI WT exchanged myofibrils. Figure 4D demonstrates that the k ACT / k TR ratio did not change upon introduction of cTnI P83S mutation.
The myofibrils were rapidly deactivated by a second switching from activating [Ca 2+ ] solution to relaxing solution (pCa 9.0), which induced a biphasic relaxation: an initial linear and slow decay followed by a rapid (fast) exponential tension decay back to the baseline (see the example tension trace in the inset of Figure 4) . The slow-phase relaxation rate (k REL,slow ) predominantly reflects the cross-bridge detachment rate, 49,53,63−66 and the duration of slow-phase relaxation (t REL,slow ) represents the time for the troponin to move back to a "blocked" state. 67 For maximal activations, both k REL,slow (0.9 ± 0.1 s −1 vs 1.0 ± 0.1 s
, Figure 6C ) and t REL,slow (72 ± 3 ms vs 71 ± 2 ms, Figure 6D ) were unchanged for cTnI P83S exchanged myofibrils compared to cTnI WT exchanged myofibrils. In contrast to slow-phase, the much larger, fast-phase of relaxation (k REL,fast ) is influenced by multiple sarcomeric properties as well as uneven relaxation between sarcomeres in series. 67 k REL,slow was twice as fast at pCa 5.4 compared to the maximal activation (pCa 4.0) for all myofibrils (Table 1) . cTnI-P83S Mutation Blunts the PKA Effects on Myofibril Contraction and Relaxation. We next studied the effects of PKA-mediated phosphorylation on myofibril contraction and relaxation. Consistent with previous studies, 10, 34 with PKA treatment, T MAX (71.1 ± 6.5 mN/mm 2 , Figure 5A ) was maintained for the cTnI WT exchanged myofibrils, and pCa 50 was right-shifted 0.18 pCa units to 5.14 ± 0.03 ( Figure 5B ), demonstrating the reduced Ca 2+ sensitivity of tension development. At maximal Ca 2+ level (pCa 4.0), PKA phosphorylation of cTnI WT exchanged myofibrils also decreased k ACT , whereas k TR was maintained, suggesting that PKA phosphorylation affects the thin filament activation prior to cross-bridge binding and tension development. The above result can be clearly observed in the plots of the k ACT /k TR ratio from Figure 5D , demonstrating that this ratio is significantly decreased for PKA treated cTnI WT exchanged myofibril compared with the ones prior to PKA treatment. After treating the cTnI P83S exchanged myofibrils with PKA, T MAX (70.3 ± 3.9 Figure 6 . Slow-phase relaxation at submaximal Ca 2+ level for (A) WT-cTn and (B) cTnI P83S cTn exchanged rat cardiac myofibrils before (black) and after (red) PKA treatment. The kinetics (C; k REL,slow ) and duration (D; t REL,slow ) of slow-phase relaxation for cTnI WT vs cTnI P83S exchanged myofibrils prior to and after PKA treatment. *p < 0.05.
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Article mN/mm 2 , Figure 5A ) was also maintained; however, the Ca 2+ sensitivity of tension development (pCa 50 , Figure 5B ) was not reduced (blunted) for cTnI P83S . Additionally, maximal k ACT did not change for cTnI P83S exchanged myofibrils following PKA phosphorylation, which can be clearly seen by calculating the k ACT /k TR ratio ( Figure 5D ), suggesting the slowed thin filament activation at maximal Ca 2+ condition was also blunted. A major influence of β-adrenergic stimulation on cardiac function is increasing heart rate, such that the rate of chamber relaxation needs to increase to allow for preserved diastolic filling. Thus, we studied how myofibril relaxation was influenced following PKA treatment of cTnI WT , Figure 6C ) and reduced t REL,slow (63 ± 3 ms, Figure 6D ) during maximal Ca 2+ activation, thus speeding up the overall relaxation. Furthermore, the above effect was greater at submaximal Ca 2+ level (pCa 5.4) where the heart operates. However, after treating the cTnI P83S exchanged myofibrils with PKA, there was no change in either the rate (1.1 ± 0.2 s −1 , Figure 6C ) or the duration (74 ± 3 ms, Figure 6D ) of the slow-phase relaxation, suggesting that the effect of PKA phosphorylation on accelerating relaxation was blunted for cTnI P83S mutation. The above finding can be clearly observed in Figure 6A ,B, which is a set of example tension traces of slowphase relaxation at submaximal Ca 2+ level.
Molecular-Dynamics Simulations. Triplicate 150 ns MD simulations (three independent 150 ns simulations) were performed on both systems, the cTnI P83S cTn system and the cTnI P83S/S23D/S24D cTn system. Our first goal was to assess the effect of introduction cTnI P83S mutation on the dynamics of cTn complex. To compare the dynamics of cTnI WT versus cTnI P83S cTn, triplicate MD simulations were performed and average RMSF (±SD) values for all residues were calculated. Figure 7A ,B shows the average (±SD) RMSF of the cTnC and cTnI subunits for both cTnI WT and cTnI P83S cTn systems. As we previously saw for cTnI R21C and cTnI R146G mutations, 34 the fluctuations in the cTnI P83S mutant were comparable to those in the WT system throughout most of the protein structure. The only pronounced difference was seen in the C-terminal domain of cTnC (cTnC residues 115−130), the loop connecting the two C-terminal cTnC EF-hand motifs (that interacts with the cTnI I−T arm). This is one direct consequence of cTnI P83S , which located in the I−T arm region. Most other regions did not exhibit changes larger than the standard deviations. The largest fluctuations were observed in the NcTnI region, underscoring its highly flexible nature. With fluctuations this large, it is appropriate to refer to a range of conformations for NcTnI rather than an actual single structural conformation. The helical bundle known as the I−T arm (cTnI residues 45− 82 and 91−137) comprised the most stable residues in the cTnI subunits, reflecting their structural rather than regulatory Figure 7A ,B also highlights regions of cTn that play an important part in either Ca 2+ binding (cTnC site I and cTnC site II) or cTnC−cTnI interaction (cTnI inhibitory-peptide and cTnI switch-peptide). In summary, cTnI P83S had little impact on the dynamics of the troponin complex.
Next, we investigated the influence of PKA phosphorylation on cTn containing cTnI P83S . To that end, we performed simulations with simultaneous phosphomimic substitutions S23D and S24D and P83S of cTnI (cTnI P83S/S23D/S24D ) in the troponin structure. Figure 7C ,D shows the average (±SD) RMSF of the cTnC and cTnI subunits for the cTnI P83S and the cTnI P83S/S23D/S24D systems. The fluctuations in the cTnI P83S/S23D/S24D system were increased with respect to the cTnI P83S system. Interestingly, there were increased dynamics in the entire structure of NcTnC, suggesting NcTnI mobility can have a profound influence on NcTnC dynamics. We also speculate that structural destabilization of cTnI (caused by the introduction of three amino acids substitutions) could be partially responsible for the wide range of RMSF values observed. The largest change of dynamical behavior between the two systems is observed in cTnI residues 20−30 where an increase in local residue fluctuations is observed. The Ser (S) to Asp (D) mutations break stabilizing interactions in the region, suggesting a large increase in the mobility of NcTnI. To better visualize how introduction of the P83S and/or bis-phosphomimic substitutions influences the subunit interactions among the cTn complex, 15 snapshots taken from the entire MD simulations were superimposed ( Figure 7E,F) . For both structure alignments, cTnC is shown in blue, cTnI in red, and cTnT in yellow. In addition to the greater flexibility exhibited for the NcTnI in the cTnI S23D/S24D cTn model with respect to the WT model, the introduction of S23D/S24D to the cTnI P83S model also caused increased flexibility in NcTnC. In addition to the change in entire protein dynamics/ structures, we investigated how the cTnI P83S mutation and/or PKA phosphorylation impact Ca 2+ binding stability in site II. It is very difficult to accurately calculate binding affinities of Ca 2+ , due to the nature of divalent cations. Therefore, we investigated one parameter related to the Ca 2+ binding in site II in cTnC, the time evolution of distances between the bound Ca 2+ ion and its coordinating residues. In the crystal structures, Ca 2+ is coordinated with six atoms in cTnC site II residues: Asp-65 OD2, Asp-67 OD2, Ser-69 OG, Asp-73 OD2, Glu-76 OE1, and Glu-76 OE2. As observed in previous studies, 34, 35, 39, 62 the coordinating behavior of Asp-65, Asp-67, Asp-73, and Glu-76 did not change for WT cTn in the absence or presence of cTnI-S23D/S24D. The most interesting behavior is observed for Ser-69 OG and, perhaps, Thr-71 OG1. Figure 8 shows those distances over the time course of three independent 150 ns simulations for WT, cTnI P83S , and cTnI P83S/S23D/S24D cTn , and cTnI P83S/S23D/S24D cTn systems. Here, the 1st run result is shown in black, the 2nd run result is in red, and the 3rd run result is in blue.
The Journal of Physical Chemistry B Article systems. The coordination behavior for both residues fluctuated over the course of the simulations for all three systems, in contrast to the stability of the other coordinating residues. Thr-71 generally does not coordinate, in agreement with structural data from X-ray crystallography. As demonstrated in Figure 8 , the most pronounced difference between the simulations is observed in coordination of Ser-69, which is consistent with our previous observations. 34, 35, 39, 62 The percent-in-contact time of Ser-69 varies among the different systems. With respect to the WT system (10%), the percent-in-contact time is increased to 19% in the cTnI P83S system, indicating a stronger interaction and a possible stabilization. This may interpret the increased Ca 2+ binding affinity of cTnI P83S with respect to the cTnI WT observed from steady-state fluorescence measurements. Importantly, this contact time was not affected by introduction of the bis-phosphomimic substitutions (17% in the cTnI P83S/S23D/S24D system), in agreement with the unchanged Ca 2+ binding affinity (K Ca ) obtained from the steady-state fluorescence measurements.
Next, we monitored the residue−residue contacts of key regions during the time course of entire 450 ns simulations. We first focused on elucidating the intrasubunit contacts between NcTnI (cTnI residues 1−41) and the cTnI inhibitory-peptide (cTnI residues 138−147). It has been previously shown that this may constitute an important mechanism by which PKA can regulate cTn structure and dynamics. The following interesting question arises: To what degree does the mutation cTnI P83S impact that mechanism? We hypothesized that, due to its distance from NcTnI and the inhibitory-peptide, cTnI P83S may not disrupt this mechanism that blunts PKA-mediated modulation of myofibril contraction and relaxation as much as other mutations (cTnI R21C and cTnI R146G ). 34, 35 To this end, we examined intrasubunit contacts between NcTnI (cTnI residues 1−41) and the cTnI inhibitory-peptide (cTnI residues 138−147). Figure 9 shows the corresponding contact plots for (A) WT, (B) cTnI-S23D/S24D, (C) cTnI-P83S, and (D) cTnI-P83S/S23D/S24D, cTn complexes. As previously reported, 62 there were no intrasubunit interactions between cTnI inhibitory-peptide and its N-terminus in the WT cTn system (see panel A), which changed dramatically with the cTnI S23D/S24D substitutions where all three independent runs formed contacts between cTnI residues 9−14 and 140−142 for about 50% of the simulation time (panel B). No intrasubunit interactions were seen in the cTnI P83S system (panel C), which Figure 9 . Average contact map of residue−residue pairs between the N-terminus (residues 1−41) and inhibitory-peptide region (residues 138−147) of cTnI for the (A) WT, (B) cTnI-S23D/S24D, (C) cTnI-P83S, and (D) cTnI-P83S/S23D/S24D cTn models. The blue end of the spectrum (value 0) reflects no contact within the residue−residue pair, while the red end of the spectrum (value 1) represents 100% contact within the residue− residue pair.
Article is not surprising since no phosphomimic substitutions or phosphorylations are present. As we expected, introduction of the cTnI P83S mutation only moderately reduced the NcTnI− cTnI inhibitory-peptide interactions in the bis-phosphomimic system (cTnI P83S/S23D/S24D , panel D). This suggests that interference with PKA regulation may be a mechanism (albeit not a strong one) of action of the cTnI P83S mutation. To further examine the region with direct contact between cTnC and cTnI with Ca 2+ binding, we next studied the contact stability between the switch-peptide of cTnI (cTnI residues 148−164) and the 14 hydrophobic NcTnC residues (Phe-20, Ala-23, Phe-24, Ile-26, Phe-27, Ile-36, Leu-41, Val-44, Leu-48, Leu-57, Met-60, Phe-77, Met-80, and Met-81). Figure 10 displays the different contact maps of residue−residue pairs between those 14 hydrophobic residues of NcTnC and the cTnI switch-peptide for different systems. As we mentioned previously, 34 Ca 2+ and the switch-peptide of cTnI were present at the beginning of the MD simulations (and we did not remove Ca 2+ during MD simulations); thus, we did not expect to observe dramatic structural changes is this region. However, a variation in the contacts can be considered as an indicator of the cTnC−cTnI interaction (K C−I ) stability associated with activation. As compared with the WT cTn complex, there was some change in contact time upon introduction of the P83S mutant (panel A). A more dramatic change was seen upon introduction of the bis-phosphomimic substitutions to S23/S24 of the WT complex (cTnI-P83S/S23D/S24D), suggesting there was a decreased interaction between NcTnC hydrophobic residues and cTnI switch-peptide upon phosphorylation (panel B). With introduction of the bis-phosphomimic substitutions to the cTnI-P83S system (panel C), there was still some visible change in fluctuation for the contacts, but the degree (net change) of fluctuation is smaller than that for the WT complex. Together with the information for the intrasubunit contact of cTnI (Figure 9 ), our MD simulations suggest that phosphorylation of S23/S24 of cTnI results in the formation of an intrasubunit contact between cTnI inhibitory-peptide and NcTnI, which further reduces the stability of the interaction between cTnI switch-peptide and the cTnC hydrophobicpatch, and cTnI P83S moderately abrogates this action. This suggests a potential structure-based mechanism of how cTnI P83S may impair PKA regulation of contraction and relaxation.
■ DISCUSSION cTnI P82S (cTnI P83S in rodents) has been considered as a potential disease-causing mutation, 16 but others suggest it may be a benign polymorphic variant rather than a disease-causing one. 17 Recently, Ramirez-Correa et al. demonstrated that cTnI P83S resulted in mild diastolic dysfunction in aging mice. 18 However, this mutation itself has not yet been reported to cause HCM in patients. So, it is of importance to study whether cTnI P82S alters myofibril contractile properties, and whether the alterations of structural-function for cTnI P82S are similar to other HCM-associated cTnI mutations. In this study, we characterized the effects of cTnI P83S on structure−function relationship of cTn and on the contractile properties of rat left ventricular myofibrils, to compare with similar measurements made previously with other cTnI mutations that have been associated with HCM. Two HCM-associated mutations, cTnI R146G and cTnI R21C (located in the inhibitory-peptide and cardiac-specific N-terminus of cTnI, respectively), not only altered normal contractile properties, but also blunted the regulatory ability of PKA-mediated phosphorylation on S23/ S24 during β-adrenergic stimulation, and we attributed this to the disruption of the formation of an intrasubunit contact between cTnI inhibitory-peptide and NcTnI that is normally seen with phosphorylatin. 34, 20 To understand whether these changes in contractile properties occur in all putative HCM cTnI mutations or are restricted to the mutations located in specific regions (such as N-terminus, inhibitory-peptide region), in this work, we studied the cTnI P83S mutation that 
Article is resided in the I−T arm region. The most significant findings for the current study were the following, compared to cTnI WT : (1) cTnI P83S increased both K Ca and K C−I , but may limit or eliminate the ability of S23/S24 phosphorylation to reduce these properties of cTn. (2) cTnI P83S had no effect on T MAX or the Ca 2+ sensitivity of myofibril tension, but blunted PKAphosphorylation-associated decrease in pCa 50 . (3) cTnI P83S at least partially blunted the PKA-mediated acceleration of the early, slow-phase of relaxation, and this may be correlated with moderate inhibition of an intrasubunit interaction between the cTnI inhibitory-peptide and NcTnI.
Comparison of cTnI P83S with cTnI R146G and cTnI
R21C
Effects on cTn and Myofibril Function. T MAX was maintained for cTnI P83S exchanged myofibrils, as we previously observed for cTnI R146G or cTnI R21C exchanged myofibrils. 34 However, while the Ca 2+ sensitivity of tension (pCa 50 ) was leftshifted by 0.13 or 0.10 pCa units for cTnI R146G or cTnI R21C exchanged myofibrils, 34 a left-shift of pCa 50 was minimal (0.04 pCa units) and not statistically different (P > 0.05) for cTnI P83S exchanged myofibrils. As we mentioned previously, C−I interaction serves as a "gatekeeper" in transmitting the Ca 2+ signal to other myofilament proteins to initiate cardiac muscle contraction and tension development. Our myofibril results were in agreement with the steady-state fluorescence measurements where the K C−I was left-shifted for cTnI P83S ; however, the extent of increment was smaller than those for cTnI R146G and cTnI R21C . 34 This result also correlated well with the steadystate cTn fluorescence measurements where the Ca 2+ sensitivity of the fluorescence intensity increase (pCa 50 ) was only leftshifted 0.09 pCa units for cTnI P83S , which is also smaller than those for cTn with cTnI R146G (0.24 pCa units) or cTnI R21C (0.22 pCa units). 34 Here, it is important to point out that the magnitude of pCa 50 change (increment or decrease) is variant in different systems, such as the net change of pCa 50 for Ca 2+ sensitivity of tension was smaller than those in the steady-state Ca 2+ −cTn binding. To understand its structural basis, we monitored the time-evolution of distances between the Ca 2+ ion (site-II) and its six coordinating residues over the time course of total 450 ns MD simulations. The percent-in-contact time can partially act as an indicator to suggest a strong interaction and a possible stabilization with Ca
2+
. We found that coordination of Ser-69 with Ca 2+ was increased to 19% for cTnI P83S mutation (Figure 7 ), a smaller value than that for either cTnI R146G (29%) or cTnI R21C (23%), which is consistent with our steady-state Ca 2+ −cTn binding affinity measurement. 34, 35 Taken together, these results suggest cTnI P83S behaves midway between two severe HCM-associated cTnI mutations and WT cTnI, suggesting it has a more moderate effect on cTn function. The effect of cTnI P83S on myofibril activation was similar to what we have reported for cTnI R146G and cTnI R21C . When comparing the Ca 2+ -dependent thin filament activation protocol (k ACT ) with the rapid release−restretch protocol (k TR ) for the same activation trial, k TR was faster than k ACT at all Ca 2+ levels we tested, for both cTnI WT and cTnI P83S exchanged myofibrils (at 15°C). This result is in accordance with our previous observations in rodent (and canine) heart. 10, 34, 49, 54 However, it is different from several other reports of no difference between k ACT and k TR , 63, 67 and we have demonstrated that this is due to the lack of a phosphate mop in our solutions, which results in the presence of 0.5 mM P i (a level of P i that is close to the physiological level of P i present in the heart) in our solutions. 10 The presence of P i specifically influences the cross-bridge tension generating isomerization, and not affecting the kinetics for thin filament activation. 49 Thus, all three mutations do not appear to affect the thin filament activation kinetics in the absence of β-adrenergic stimulation.
During the slow-phase relaxation, subsequent to rapid reduction in Ca 2+ , the sarcomeres still maintain in isometric conditions, such that the tension decays with a linear, constant rate. Thus, k REL,slow monitors the turnover kinetics of crossbridge cycling, dominated by the detachment rate. 49 ( Figure 5B). Additionally, the k ACT /k TR ratio was decreased from 0.67 to 0.52 for cTnI WT exchanged myofibrils upon PKA treatment, suggesting a slowed thin filament activation process. Interestingly, the k ACT /k TR ratio did not differ with PKA phosphorylation for cTnI P83S , which is similar to what we reported for cTnI R146G and cTnI R21C . Also similar was the observation that cTnI P83S blunted the ability of PKA to speed the early, slow-phase of myofibril relaxation ( Figure 6 ). Using steady-state fluorescence measurements, we found that introduction of the bis-phosphomimic substitutions on cTnI resulted in a quite similar reduction of the Ca 2+ binding affinity to cTn (K Ca ) for all complexes (expect cTnI P83S ). However, the decrease of C−I interaction (K C−I ) observed in cTnI WT did not occur for all three cTnI mutations. Those findings suggest that it may be the alteration of C−I interaction per se that perturbs (blunt) the modulation of PKA-mediated phosphorylation (on S23/S24 of cTnI) on altering the contractile properties for at least some cTnI mutations associated with HCM. It is of importance to point out that, in regard to the steady-state C−I binding measurements (in the presence of Ca 2+ ), there are at least two kinds of C−I interactions (the hydrophobic batch of cTnC with switch-peptide of cTnI, and the cTnC with the Nterminus of cTnI, etc). We also measured the C−I binding in the absence of Ca 2+ (date not present), and the K C−I values were saturated more slowly and were right-shifted (compared to the presence of Ca 2+ condition) for all cTnI variants. In the absence of Ca 2+ , the regulatory domain of cTnC was in the closed conformation, and cTnI may just nonspecifically bind to cTnC, such that the C−I binding without Ca 2+ is not a good indicator. On the other hand, the presence of Ca 2+ induces an "open" confirmation of the NcTnC, and allows the hydrophobic-patch of cTnC to interact with the switch-peptide of cTnI. Together, although it is hard to only measure the C−I binding between the hydrophobic-patch of cTnC with the switch-peptide of cTnI, it is the primary C−I binding portion in the presence of Ca 2+ . Additionally, the presence of Ca 2+ is relevant to the physiology conditions that lead to muscle contraction and tension production. 70−72 Using the in vitro motility assay, Deng et al. reported that cTnI R145G mutation suppressed the PKA effects on the maximal vitro sliding velocity and maximal actoS1-ATPase activity. 19 By exchanging the cTn complex into skinned rat trabeculae, Biesiadecki et al. found that cTnC G159D mutation blunted the PKA phosphorylation induced decrease in the Ca 2+ sensitivity of tension development (pCa 50 ). 69 Using an in vitro motility assay, Messer et al. reported that seven HCM-associated mutations in cTnT uncoupled the modulation of Ca 2+ sensitivity by PKA phosphorylation of cTnI. 73 To mimic PKA phosphorylation, we built up a bis-phosphomimic (cTnI S23D/S24D cTn) model by mutating the S23/S24 of cTnI to aspartic acid (D). Despite the charge and molecular space of real phosphorylation and the phosphorylation mimetics being different, the cTnI S23D/S24D substitution has previously been demonstrated to mimic the effects of PKA phosphorylation on S23/S24 of cTnI (cTnI pS23/pS24 ) both structurally and functionally. 76 , which had phosphorylated serine residues mutated to aspartic acid, served as a good structural mimetic of the phosphorylated state and would facilitate future biophysical studies. 76 Following this, several groups (including ours) have used the cTnI S23D/S24D substitution instead of the cTnI pS23/pS24 to study the effects of PKA-mediated phosphorylation on cardiac function, as it serves as a useful tool to study the specific effect of PKA-mediated phosphorylation of cTnI, in the absence of cMyBP-C and titin phosphorylation that also occurs during β-adrenergic stimulation. 80, 81 As we reported previously, introduction of the bisphosphomimic substitutions at S23/S24 led to the formation of an intrasubunit interaction between the N-terminus and the inhibitory-peptide regions of cTnI for WT cTn simulations, 62 which has been previously proposed by Solaro et al. based on the spectroscopic and solution biochemistry measurements. 13, 56, 82 Additionally, our simulation results suggested a bending at the N-terminus of cTnI and the formation of a more compact cTn structure with the introduction of bisphosphomimic substituions (on WT-cTn), which is in accordance with the biochemical studies by several other laboratories. 83−85 Interestingly, this intrasubunit interaction no longer occurs in the presence of either cTnI R146G or cTnI R21C . This result was not surprising since these mutations are located in the interacting regions, either the inhibitory-peptide (cTnI R146G ) or N-terminus (cTnI R21C ) of cTnI, which may directly inhibit the formation of intrasubunit contacts between these two regions. However, cTnI P83S resides in the I−T arm of cTnI and does not directly interact with either region. Thus, our finding that there is still a moderate amount of intrasubunit interaction (though reduced) makes sense and may explain the lesser influence of cTnI P83S (compared with cTnI R146G or cTnI R21C ) in blunting PKA-mediated modulation of function. Our findings may at least partially explain the contradictory reports and conclusions in the literature of cTnI P82S . Taken together, it suggests that cTnI P82S could contribute to a hypertrophic phenotype in the heart, but it would likely require an additional causal genetic mutation or epigenetic conditions. This is correlated to what Frazier et al. reported previously, in which an African American individual with severe HCM had identified mutations both in cTnI P82S and MYH7 R453S . 17 Finally, there are some limitations present in the current study, such as the following: (1) We did not do protein studies looking at the interaction of the N-terminal extension of cTnI with the inhibitory-peptide. This would have to be done with NMR and would have its own limitations because you cannot study whole cTn with NMR. (2) We did not measure Ca 2+ dissociation rate or cTnC−cTnI interaction in myofibrils. For exploring a future direction, we can introduce some techniques (such as FRET) to our myofibril mechanics/kinetics setup, thus allowing us to collect the kinetics results accompanied with the information related to structural alteration.
■ CONCLUSION
The cardiac troponin (cTn) complex plays a pivotal regulatory role in myofilament contraction and tension generation. Studying how disease-related mutations affect conformational changes in cTn provides insight as to how Ca 2+ -mediated signal transduction may be altered and may result in contractile dysfunction associated with cardiac disease (the correlations between genotype and phenotype). Recently, we reported the altered structure−function relationship for two HCM-associated cTnI mutations, located in either the inhibitory-peptide (cTnI R146G ) or cardiac-specific N-terminus of cTnI (cTnI R21C ). 34, 35 Our results suggested that the structural basis of how both mutations blunted the ability of PKA-mediated phosphorylation to modulate both contraction and relaxation is prohibiting the formation of an intrasubunit interaction between the inhibitory-peptide and N-terminus of cTnI. 34, 35 Here, we expanded this information to a mutation (cTnI P83S ) that is not located in those specific regions, and the possible (potential) mechanism of how this mutant may alter the cardiac function. Our findings also partially explain the contradictory reports of cTnI P82S in the literature, and proposed that cTnI P82S possibly requires additional conditions to contribute to a hypertrophic phenotype in the heart. Taken together, the combination of experimental (such as solution protein biochemistry, myofibril mechanic and kinetics measurements) and computational (MD simulations) approaches provides a powerful interdisciplinary to understand the molecular mechanisms of how disease-related mutations (and PKAmediated phosphorylation on myofilament proteins during β-adrenergic stimulation) affect the structure−function relationship.
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